Aspirin
Drug325 mg enteric coated single dose p.o.
NCT Number: NCT00948987
The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
325 mg enteric coated single dose p.o.
Time frame: 8 hours postdose
Time frame: 8 hours postdose
University of Pennsylvania
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06716255
Arterial Occlusive Diseases, Arteriosclerosis
Moscow, Russia
View Trial DetailsNCT01104441
Arterial Occlusive Diseases, Arteriosclerosis
Bordeaux, France
View Trial DetailsNCT01432652
Aspirin Resistance
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT01159639
Arterial Occlusive Diseases, Arteriosclerosis
Zagreb, Croatia
View Trial Details